

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Hansoh Pharmaceutical Group Company Limited

翰森製藥集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 3692)

VOLUNTARY ANNOUNCEMENT

MARKETING AUTHORIZATION APPLICATION OF AUMOLERTINIB IN THE EU RESUBMITTED AND VALIDATED BY THE EMA

Reference is made to the announcement of Hansoh Pharmaceutical Group Company Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) dated September 27, 2026 in respect of the update on the marketing authorization status of Aumolertinib, marketed as Aumsega® outside China, in the European Union (the “**EU**”). Unless the context otherwise requires, capitalized words and expressions used herein shall have the same meanings as defined in the said announcement.

The board of directors (the “**Board**”) of the Company announces that, on September 29, 2026, the Group resubmitted the marketing authorization application (the “**MAA**”) of innovative medicine Aumolertinib in the EU to the European Medicines Agency (the “**EMA**”), and, on October 7, 2026, the EMA has validated the new MAA and the centralized review procedure has officially commenced. The indications are for: (i) the first-line treatment of adult patients with advanced non-small cell lung cancer (“**NSCLC**”) whose tumours have Epidermal Growth Factor Receptor (“**EGFR**”) exon 19 deletions or exon 21 (L858R) substitution mutations; and (ii) the treatment of adult patients with advanced EGFR T790M mutation positive NSCLC.

By Order of the Board
Hansoh Pharmaceutical Group Company Limited
Zhong Huijuan
Chairlady

Hong Kong, October 11, 2026

As at the date of this announcement, the Board comprises Ms. Zhong Huijuan as chairlady and executive director, Ms. Sun Yuan and Dr. Lyu Aifeng as executive directors, and Mr. Lin Guoqiang, Mr. Chan Charles Sheung Wai, Ms. Yang Dongtao and Mr. Yan Jia as independent non-executive directors.